公开(公告)号：US20130149281A1

公开(公告)日：2013-06-13

申请号：US13764509

申请日：2013-02-11

Applicant: NOVARTIS AG

Inventor： Trixi Brandl ,  Jiping Fu ,  Francois Lenoir ,  David Thomas Parker ,  Michael Patane ,  Branko Radetich ,  Prakash Raman ,  Pascal Rigollier ,  Mohindra Seepersaud ,  Oliver Simic ,  Aregahegn Yifru ,  Rui Zhang

IPC: A61K38/07 ,  A61K45/06 ,  A61K38/06

CPC classification number: A61K38/07 ,  A61K38/00 ,  A61K38/06 ,  A61K45/06 ,  C07D209/96 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D487/10 ,  C07D491/20 ,  C07D495/10 ,  C07D498/04 ,  C07D498/10 ,  C07K5/06034 ,  C07K5/06078 ,  C07K5/06165 ,  C07K5/0808 ,  C07K5/0812 ,  C07K5/101 ,  C07K5/1016

Abstract: The present application describes a method of treating an HCV-associated disorder by administering to a subject in need thereof a pharmaceutically effective amount of a compound of formula I in combination with an additional HCV-modulating compound.

Abstract translation: 本申请描述了通过向有需要的受试者施用药学有效量的式I化合物与另外的HCV调节化合物组合来治疗HCV相关疾病的方法。

公开(公告)号：US12209144B2

公开(公告)日：2025-01-28

申请号：US17296679

申请日：2019-11-26

Applicant: Novartis AG

Inventor： Alec Nathanson Flyer ,  Andrei Alexandrovich Golosov ,  Philipp Grosche ,  Ian Lewis ,  Eugene Yuejin Liu ,  Andreas Marzinzik ,  Lauren Gilchrist Monovich ,  Johannes Ottl ,  Tajesh Jayprakash Patel ,  Patrick Crawford Reid ,  Mohindra Seepersaud

IPC: C07K7/64 ,  A61K38/12 ,  A61K45/06 ,  A61K38/00

Abstract: The disclosure relates to inhibitors of PCSK9 useful in the treatment of lipid metabolism, and other diseases in which PCSK9 plays a role, having the Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, wherein R1, X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12, and X13 are described herein.